Pharma Equity Group
Pharma Equity Group is a pharmaceutical investment group dedicated to supporting its subsidiary, Reponex Pharmaceuticals, in developing new effective medicines for the local treatment of serious, acute, and chronic inflammatory diseases. The company focuses on early-stage biotechnology investments, fostering innovation, and creating a cost-efficient, flexible environment to accelerate drug development and market access.
Industries
Nr. of Employees
small (1-50)
Pharma Equity Group
Slotsmarken 18, 2.th., DK-2970 Hørsholm, Denmark
Products
Pipeline of repositioned local drug candidates
A portfolio of repositioned pharmaceutical candidates designed for local administration to treat serious acute and chronic inflammatory conditions; candidates are at clinical stages including Phase II.
Pipeline of repositioned local drug candidates
A portfolio of repositioned pharmaceutical candidates designed for local administration to treat serious acute and chronic inflammatory conditions; candidates are at clinical stages including Phase II.
Services
Strategic capital, governance and business-development support focused on advancing early-stage biopharmaceutical assets toward clinical milestones and market-readiness.
Support for clinical-stage development including trial planning, regulatory engagement and quality oversight to progress candidates to Phase II.
Strategic capital, governance and business-development support focused on advancing early-stage biopharmaceutical assets toward clinical milestones and market-readiness.
Support for clinical-stage development including trial planning, regulatory engagement and quality oversight to progress candidates to Phase II.
Expertise Areas
- Clinical trial management and Phase II development
- Local drug delivery and formulation development
- Drug repositioning and repurposing
- Regulatory compliance and quality systems (GCP/GMP/GDP)
Key Technologies
- Local (site-directed) drug delivery
- Formulation development for targeted administration
- Drug repositioning methodologies
- Clinical protocol design and execution
News & Updates
The general meeting was held on April 21, 2022, with Advokat Martin Allan Christensen appointed as chairman.
Blue Vision A/S called for an extraordinary general meeting on October 27, 2022.
Blue Vision A/S announced a conditional purchase offer for Reponex Pharmaceuticals A/S on April 6, 2022.
Blue Vision A/S completed due diligence for the acquisition of Reponex Pharmaceuticals A/S in August 2022.
Blue Vision A/S has selected Reponex Pharmaceuticals A/S as the target company for new activities, indicating strategic development plans.
Reponex Pharmaceuticals was listed on the Nasdaq Copenhagen Stock Exchange on March 28, 2023.
The general meeting was held on April 21, 2022, with Advokat Martin Allan Christensen appointed as chairman.
Blue Vision A/S called for an extraordinary general meeting on October 27, 2022.
Blue Vision A/S announced a conditional purchase offer for Reponex Pharmaceuticals A/S on April 6, 2022.
Blue Vision A/S completed due diligence for the acquisition of Reponex Pharmaceuticals A/S in August 2022.
Blue Vision A/S has selected Reponex Pharmaceuticals A/S as the target company for new activities, indicating strategic development plans.
Reponex Pharmaceuticals was listed on the Nasdaq Copenhagen Stock Exchange on March 28, 2023.